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Abstract
Despite the wealth of genomic and transcriptomic data in Parkinson’s disease (PD), the initial molecular events are unknown. 
Using LD score regression analysis, we show significant enrichment in PD heritability within regulatory sites for LPS-
activated monocytes and that TLR4 expression is highest within human substantia nigra, the most affected brain region, 
suggesting a role for TLR4 inflammatory responses. We then performed extended incubation of cells with physiological 
concentrations of small alpha-synuclein oligomers observing the development of a TLR4-dependent sensitized inflamma-
tory response with time, including TNF-α production. ROS and cell death in primary neuronal cultures were significantly 
reduced by TLR4 antagonists revealing that an indirect inflammatory mechanism involving cytokines produced by glial cells 
makes a major contribution to neuronal death. Prolonged exposure to low levels of alpha-synuclein oligomers sensitizes 
TLR4 responsiveness in astrocytes and microglial, explaining how they become pro-inflammatory, and may be an early 
causative event in PD.
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Introduction
Parkinson’s disease (PD) is a common progressive neurode-
generative disease with motor-related symptoms including 
tremor, bradykinesia and rigidity and characterized by the 
loss of dopaminergic neurons in the substantia nigra and the 
presence of Lewy bodies containing deposits of the protein 
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alpha-synuclein (α-syn). Genome-wide association studies 
(GWAS) have identified several genes including SNCA, to be 
associated with sporadic PD [28] but the molecular causes 
of the disease and in particular the initial early events that 
lead to the onset of PD are still largely not understood nor 
is it understood why the dopaminergic neurons are particu-
larly vulnerable. The aggregation of α-syn, neuroinflamma-
tion and oxidative stress all occur during the progression of 
PD, however, which of these processes occurs first and then 
initiates the others remains to be established. The temporal 
order that the initial events occur in matters if one wants to 
develop treatments for PD that tackle the underlying cause 
of the disease.
Neuroinflammation in the brain can be protective but 
there is evidence that with prolonged activation it becomes 
destructive, playing an important role in the development 
of neurodegeneration in general and PD in particular [49]. 
Neuroinflammation is characterised by activation of micro-
glial cells and astrocytes resulting in increased production 
of cytokines and other pro-inflammatory mediators [54] and 
can be activated by extra-cellular aggregates of α-syn. Pat-
tern recognition receptors (PRR), such as toll-like receptors 
(TLRs) detect pathogens which induce inflammation in cells 
such as macrophages and microglia to control infections [4]. 
TLR4 senses the Gram-negative bacterial outer membrane 
component lipopolysaccharide (LPS) and TLR2 detects 
bacterial lipoproteins, however, both receptors also detect 
endogenous danger-associated molecules such as proteins 
produced during tissue damage. Activation of TLR4 and 
TLR2 recruits myeloid differentiation primary response gene 
88 (MyD88) to its cytosolic toll/IL-1R (TIR) domain via 
the adaptor protein MyD88 adaptor-like (Mal). TLR4 also 
recruits a second signalling adaptor protein, TIR domain-
containing adaptor-inducing interferon-beta (TRIF), via the 
TRIF-related adaptor molecule (TRAM). It is now clear that 
oligomeric proteins such as α-syn are recognised by TLRs 
2 and 4 [6, 8, 13, 15, 25, 42, 54]. TLRs are also upregulated 
in the brains of patients with PD [12]. However, the role 
of TLRs in PD is conflicting when mouse models of the 
disease have been used. In a MPTP inflammatory model 
of PD, TLR4 knockout mice were protected [37]. In con-
trast, TLR4 promoted α-syn clearance in a synucleinopathy 
protein aggregation mouse model [45]. These contrasting 
results highlight the importance of establishing the initial 
events that cause PD in humans and the role played by TLRs. 
The role of TLRs in the development of PD is also cur-
rently unclear because the in vitro studies to date have used 
1000-fold higher protein aggregate concentrations than those 
found in the human disease (estimated at 1–10 pM oligomers 
in CSF [19, 47]), containing large uncharacterized aggre-
gates over short time courses. Yet PD is chronic in nature so 
it is difficult to extrapolate the results of these experiments 
to lower pM doses of smaller soluble aggregates, which will 
be formed initially during aggregation, over longer times. 
Furthermore, the differences in α-syn oligomer concentra-
tions between individuals with PD and healthy controls is 
small, less than a factor of two [20]. This means that healthy 
controls have pM concentrations of α-syn oligomer but do 
not develop PD and that there is only a small change in oli-
gomer concentration with the development of PD.
We have first used human genetic and transcriptomic data 
to investigate the importance of TLR2 and TLR4 in PD. 
We find evidence to suggest that TLR4 signalling plays a 
causative role and could contribute to the selective vulner-
ability of dopaminergic neurons through higher expression 
of TLR4. To understand the role of TLR4 signalling in PD, 
we then studied the response of macrophage, microglia and 
astrocytes to picomolar doses of physiological concentra-
tions of small soluble α-syn oligomers over several days. We 
find that a TLR4-mediated inflammatory response develops 
with time due to sensitization. Taking together, these results 
suggest that TLR4 signalling and the resulting neuroinflam-
mation may be one of the earliest event in PD pathogenesis.
Methods
Protein preparation
The expression and purification of wild-type α-syn was 
performed as detailed previously [7]. Bacterial endotoxins 
were removed using a detoxi-gel endotoxin removing Col-
umns (ThermoFisher scientific) according to manufacturer’s 
instruction. Levels in endotoxin-free α-syn were recorded as 
0.006 ng/ml (stomacher 80 biomaster seward) in α-syn prep-
arations (autoclaved endotoxin-free plastics and endotoxin-
free water were used at all stages of preparations). Protein 
was then aliquoted into separate eppendorfs into filtered PBS 
(0.02 μM filter, Whatman) flash-frozen, stored at − 80 °C 
and thawed once before use. Clusterin was obtained as previ-
ously described [11, 50].
TLR4 antagonists
RSLA and TAK-242 were purchased from Invivogen.
Protein aggregation
α-syn oligomers were prepared by first diluting in DMEM 
buffer (DMEM + 1% FCS + 2 mM l-glutamine). The aggre-
gation mixture was incubated for 26.5 h at 37 °C with con-
stant shaking of 200 r.p.m (New Brunswick Scientific Innova 
43, 25 mm orbital diameter) and centrifuged at 14200 rpm 
for 10 min to remove any fibrillar pellets. α-syn fibrils were 
formed by aggregation for 88 h.
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Aggregated α-syn was then stored at 4 °C until incubated 
with cells. Using thiofalvin-T (ThT) assays, oligomers and 
fibrils were found to remain stable for 1 week after removal 
from the shaking incubator, however, aggregates were 
always used within 24 h.
ThT assay
The time course of the aggregation was monitored using 
ThT assays. ThT (Sigma-Aldrich) stocks were prepared in 
DMSO (Sigma-Aldrich) and diluted into pre-filtered PBS 
(0.02 μm filter, Whatman) to a final concentration of approx-
imately 100 μM. α-syn was added to 1 ml of ThT solutions 
and binding monitored by exciting the sample at 440 nm and 
recording the emission fluorescence spectrum from 460 to 
560 nm (slit width 5 nm). Measurements were carried out on 
a Cary Eclipse spectrofluorometer with a Peltier-controlled 
holder (Varian, Mulgrave, Australia).
ThT imaging of unlabeled aggregates
ThT imaging utilized a method previously described [20]. 
Briefly, glass cover-slides (VWR international, 20 × 20 mm) 
were cleaned using an argon plasma cleaner (PDC-002, Har-
rick Plasma) for at least 1 h to remove any residual that 
fluoresces. 50 µl of poly-l-lysine (70,000–150,000 molecular 
weight, Sigma-Aldrich) was added to the cover slides and 
incubated for 1 h before being gently washed with filtered 
PBS. Imaging was performed on a custom-built total internal 
reflection fluorescence microscope.
Single‑molecule analysis of labelled aggregates
For single-molecule Förster Resonance Energy Transfer 
(sm-FRET) experiments, α-syn with the alanine to cysteine 
mutation at position 90 was used (A90C), and was singly 
labelled with maleimide-modified Alexa Fluor (AF) 488 
or 594 dyes (Life technologies) according to previously 
established protocols [7, 23] This mutation and fluorescent 
labelling were demonstrated not to significantly affect the 
aggregation properties of α-syn in our previous sm-FRET 
studies of α-syn aggregation [7, 23]. In these previous stud-
ies, reproducible conversion of initially disordered oligomers 
of α-syn to more stable and compact forms was observed 
during the lag phase of the aggregation reaction. This con-
formational conversion was demonstrated to be associated 
with an increase of oligomer cytotoxicity. Low FRET effi-
ciency values were observed in initially formed oligomers 
(thus termed “low FRET”), while stable toxic oligomers 
had characteristically high FRET efficiency values, and thus 
were termed “high FRET”. For the FRET aggregation assay, 
a 1:1 ratio of α-syn labelled with AF488 (α-syn-AF488) and 
AF594 (α-syn-AF594) was used, and the same incubation 
conditions as for other α-syn oligomer preparations (70 µM, 
37 °C, with agitation). The solutions were withdrawn after 
26.5 h, and analyzed both immediately after withdrawal and 
after 24.5 h of incubation at 37 °C without agitation, using 
sm-FRET according to previously described protocols [21]. 
In sm-FRET experiments, the α-syn solutions were irradi-
ated with a focused 488 nm laser beam, as described previ-
ously [21]. As the oligomers contained both α-syn-AF488 
and α-syn-AF594 molecules, the α-syn-AF488 non-radia-
tively excites the α-syn-AF594 via FRET process. Simul-
taneous fluorescence intensity bursts in both channels are 
observed for oligomers making them distinguishable from 
the monomeric protein in solution. The fluorescence inten-
sity values of the oligomeric bursts were used to derive 
FRET efficiency values (Eq. 1) and apparent size (Eq. 2) for 
each oligomer.The FRET efficiency values were calculated 
according to:
where IA is the corrected acceptor fluorescence intensity, 
ID is the corrected donor fluorescence intensity and γ is a 
gamma factor (0.99) specific to the instrument. FRET effi-
ciency values were represented as histograms with a bin-
width of 0.05. The oligomer apparent size was estimated 
using:
where IDmonomer was the average intensity of fluorescence 
bursts in the donor (AF488) channel after exclusion of oligo-
meric bursts. The total fluorescence intensity from AF488 is 
normalized by the average AF488 monomer brightness. The 
factor of two corrects for the 1:1 stoichiometry of AF488 
and AF594 fluorophores. Species determined to be greater 
than 150-mers or occupying multiple consecutive time-bins 
were removed from the analysis, under the assumption that 
they were either fibrillar or arising from dust. The expression 
is valid under the assumption that there is no appreciable 
quenching in the soluble oligomers. The size distributions 
are referred to as “Apparent”; serving as estimates owing to 
the stochastic nature of fluorescence emission and different 
trajectories oligomers can take through the confocal volume.
To determine the average FRET efficiency value, the 
FRET histograms of selected time points were fitted to a 
Gaussian distribution (Origin 7.0), using the following 
GaussAmp function:
(1)E =
IA
IA + 훾ID
(2)Apparent size = 2 ×
ID + 훾
−1IA
Imonomer
(3)y = y0 + A exp
(
−
(
x − xc
)2
2w2
)
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where A is the amplitude, xc is the centre, corresponding to 
average FRET efficiency value (E), and w the widths of the 
distribution.
ELISA assays
To determine cumulative TNF-α, Il-1β and nitric oxide pro-
duction, supernatants were obtained after incubation with 
the α-syn over viable time frames and stored at − 80° until 
analyzed. TNF-α and Il-1β were analyzed using the  Duoset® 
enzyme-linked immunosorbent assay (ELISA) development 
system (R&D Systems, Abingdon, Oxfordshire, UK). iNOS 
activity was determined indirectly by measuring using the 
Griess reaction [18].
Cell culture
The BV2 cell lines were derived from immortalized murine 
neonatal microglia. They were grown in Dulbecco’s Modi-
fied Eagle’s Medium (DMEM) supplemented with 10% foe-
tal bovine serum and 1% l-Glutamine (Life Technologies) 
and incubated at 37  °C in a humidified atmosphere of 5% 
 CO2 and 95% air, until approximately 1.6 ×  106 cell/ml. 
 MyD88−/−,  TLR2−/− and  TLR4−/− murine cells [22, 24, 46] 
were immortalised previously (a generous gift from Dr D 
Golenbock, UMass Medical School, USA) and grown from 
frozen stock samples under the same conditions as BV2. All 
mice are the same genetic background (C57Bl6).
Astrocytes were from a rat whole-brain mixed glial 
preparation and prepared following a published protocol 
that obtains preparations with less than 2% microglia [44]. 
The brains used were from postnatal Sprague–Dawley (SD) 
pups. After removing the meninges, the brains were pushed 
through a 40 µm filter (falcon) using Dulbecco’s Modi-
fied Eagle’s (DMEM) Medium (Invitrogen). All filtered 
brains were collected and homogenized in a falcon tube and 
spun at 1500 rpm for 5 min. The pellet was resuspended in 
DMEM media supplemented with 10% fetal bovine serum, 
1% penicillin and streptomycin and 1% l-glutamine (Life 
Technologies) (15 mls per head). Cells were plated out in 
25 mL medium per uncoated T75 flask and placed at 37 °C, 
5%  CO2 and left for 5 days to give the glia time to stick 
down and begin to proliferate. After 5 days, all medium were 
removed and replaced with 15 ml of fresh medium. Cells 
were cultured for 14 days before used in experiments and for 
no longer than 6 weeks after that time. Cells were passaged 
2–3 times a week at a confluence of 70–90% after the ini-
tial 5 days. Experiments were performed with 1–1.5 million 
cells per well. To keep the number of microglial very low, 
we changed the medium every 2–3 days and used uncoated 
flasks. The cells were sub-cultured 2–3 times per week. For 
long duration experiments, the buffer was exchanged every 
24 h.
Rodent neuron and astrocyte culture
Cultures of cortical neurons and the co-culture of neuron and 
astrocyte were prepared from embryos (E17) and postnatal 
pups of Sprague–Dawley (UCL breeding colony), respec-
tively. Cortices of the brain were placed in ice-cold dissect-
ing buffer  (Ca2+,  Mg2+-free HBSS supplemented with 20% 
fetal bovine serum, sodium bicarbonate and 5 mM HEPES) 
and washed with washing buffer (dissecting buffer without 
fetal bovine serum). The tissue was digested with EDTA 
trypsin for 15 min and neutralized with dissecting buffer 
(washing buffer supplemented with 400 KU DNAse). Pel-
lets were collected in complete neurobasal medium (Neu-
robasalA medium supplemented with B28, 2 mM Glutamax 
and 50 I.U/ml Penicillin/50 ug/ml Streptomycin). Approxi-
mately, 50,000 cells for 96-well plates and 100,000 cells for 
u-slide 8 well ibidi chamber (Thistle Scientific Ltd, Cat no: 
IB-80826) were plated. Plates were pre-coated with PDL 
at 37 °C (5%  CO2) for 2 h. Cells were used at 12–16 days 
in vitro. Cortical astrocytes were purchased from Caltag 
Med Systems (Science Cell, Cat no: R1800) which were 
derived from postnatal day 2 rat cortex. Cells were thawed 
onto pre-coated plates with PDL (2 h) at 37 °C (5%  CO2) 
containing rodent astrocyte medium (Caltag Medsystem, 
Cat no: 1831) and cultured until full confluence. 100,000 
cells were re-plated onto u-slide 8-well ibidi chambers and 
50,000 cells were plated onto 96-well plates and used within 
2–3 days.
Human cortical neuron and astrocyte culture
Human cortical neurons (Cat no: 1520) and astrocytes (Cat 
no: SC-1800) were purchased from Caltag Medsystems Ltd 
(for Sciencell). Neurons were thawed and plated onto PDL 
(2 h) and laminin (2 h) pre-coated plates at 37 °C (5%  CO2) 
containing neuron medium (Caltag Medsystem, Cat no: 
1521) and cultured for 4–5 days until use. Astrocytes were 
thawed and cultured in PDL-coated 75T flask containing 
human astrocyte medium (Caltag Medsystmes SC-1801). 
Upon full confluence, approximately 100,000 numbers of 
cells were re-plated onto a PDL-coated 8-well ibid chamber 
and 50,000 cells for 96-well plates. For co-culture prepa-
ration, astrocytes were plated on top of neurons (1:1) and 
cultured for another 3 days until use.
TNF‑α measurements in human astrocytes
Human cortical astrocytes were purchased from Caltag 
Medsystems Ltd (Cat number: SC-1800) and grown in 
a PDL-coated 75T flask containing Astrocyte medium 
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(Caltag Medsystmes SC-1801). Upon full confluence, 
approximately 150,000 numbers of cells were re-plated 
onto a PDL-coated 8-well ibid chamber (Cat number: 
IB-80826, Thistle Scientific Ltd) which requires 250 μl 
medium per well. On the following day, cells were treated 
with a range of different concentrations of α-syn oligom-
ers. The medium was collected from day 1, day 2, day 
3 and day 4, respectively, after treatment. The collected 
medium was spin down at 15,000 rpm at 4 °C for 10 min to 
remove cell debris and the supernatant was transferred into 
a 1.5 mL Eppendorf tube and then stored at –70 °C until 
use. Autoclaved endotoxin-free plastics and endotoxin-
free water was used at all stages of preparations with an 
endotoxin reading of 0.008 ng/ml recorded. The human 
astrocytes produce a response to α-syn oligomers but not 
monomer or fibrils and this response was detectable at 
oligomer concentrations as low as 5 nM after 72 h of incu-
bation (Supplementary Fig. 7). To study how TLR4 inhibi-
tors affect the release of oligomer-induced TNF-α, human 
cortical astrocytes were prepared as above. 1 μM TAK242 
or 0.1 μg/ml RSLA was pre-treated in cells prior to apply-
ing α-syn oligomers. 100 nM Clusterin was co-incubated 
with oligomer and then applied to the cells. Cells were 
incubated with each inhibitor for 24 h and then medium 
was collected as above (Supplementary Fig. 8).
ROS measurement
ROS production (mainly superoxide) was measured using 
dihydroethidium (Molecular Probe, 2 μM) as previously 
described [7]. To inhibit TNF-α activity, either RSLA 
or TAK242 were pre-incubated in the cells for 30 min 
prior to imaging and the inhibitors were present during 
the recording. Clusterin was co-incubated with oligomers 
for 30 min and then applied together for imaging. 1 μM 
α-syn monomer or an α-syn oligomeric solution contain-
ing 1 μM monomer and approximately 10 nM oligomers 
with or without a range of inhibitors (RSLA, Clusterin, 
TAK242) were applied after obtaining basal ROS. Data 
was analyzed using software from Andor II (Belfast, UK).
Cell death assay
Cell death was detected using either Sytox green (Molecu-
lar Probes) or propidium iodide (PI, Molecular Probes). 
Cells were washed once and incubated with either 0.5 μM 
Sytox green or PI and 10 μM Hoechst, nucleic marker 
(Molecular Probes) in HEPES balanced HBSS (pH 
adjusted at 7.4 with NaOH) for 15 min. Low-throughput 
measurements were performed using a Zeiss LSM 710 
with a 20× objective and the fluorescence signals were 
imaged by excitation (ex) 504 nm/emission (em) 523 nm 
for sytox green. For Hoechst staining, nuclei were imaged 
using ex 361 nm/em 497 nm to determine the total num-
ber of cells. The percentage cell death was quantified by 
the ratio between the number of green fluorescent and the 
total number of blue fluorescenct cells per image. 3–5 
fields of images were taken per well and data were ana-
lyzed using Volocity 6.3, cellular imaging and analysis 
software. High-throughput images were acquired using a 
Cellomics Insight NXT. Sytox green staining was imaged 
by green channel LED and Dapi channel LED was for the 
hoechst-stained nuclei (17–22 fields of images were taken 
per wells). The number of fluorescence-positive cells were 
determined using multi-wavelength cell-scoring module 
of HCS Studio™ Cell Analysis Software and each experi-
ment kept the same setting of the thresholds (e.g., intensity 
and size).
Statistical analysis
A sample size between 2 and 5 individual experiments per 
conditions was deemed sufficient due to the low variation 
between replicates. All p values for cell experiments where 
TNF-α production was measured are derived from a one-way 
ANOVA followed by the Tukey’s post hoc test. For live cell 
imaging (ROS measurement and cell death), there were total 
two (human) and three (rodent) independent experiments 
which include different animals, different cell batches, cell 
preparation and live-cell imaging. Each set of independent 
experiment consists of 2–3 wells per condition (for techni-
cal replicates) and the figures represent data pooled from all 
independent experiments. One-way ANOVA with a Tukey 
correction was used to test statistical significance.
Gene co‑expression network analyses of human 
brain transcriptomic data
We generated a Gene Co-expression Network (GCN) per 
brain area using expression data generated by the UK Brain 
Expression Consortium [40] and assayed with the Affym-
etrix Exon 1.0 ST Array in the following tissues: cerebellar 
cortex, frontal cortex, hippocampus, inferior olivary nucleus, 
occipital cortex, putamen, substantia nigra, temporal cor-
tex, thalamus and intralobular white matter originating from 
neuropathologically normal individuals. In total, 19,152 
microarray probesets were used by the weighted gene co-
expression network analysis (WGCNA) R package [26, 27]. 
In brief, after outlier removal, a “signed” GCN was con-
structed by creating a signed Topological Overlap Measure 
(TOM) matrix based on Pearson’s correlation. Gene modules 
were created by hierarchical clustering based on a 1-TOM 
dissimilarity matrix. The results of the initial hierarchical 
clustering were post-processed using the k-means clustering 
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search method with 30 iterations [2]. After this, gene mod-
ules were functionally annotated with gProfileR4 R pack-
age using Gene Ontology (GO) database without Electronic 
Inferred Annotations (EIA) and accounting for multiple test-
ing with gSCS.
GWAS enrichment analysis on co‑expression 
modules
To assess the enrichment of a given GWAS study at mod-
ules of a GCN, we used the GWAS summary statistics with 
VEGAS [29] to perform gene-based tests for association of 
SNPs and genes. We used HapMap CEU (Central Europe-
ans, Utah) population of reference to estimate patterns of 
linkage disequilibrium and generate a list of genes and their 
corresponding p value for significance of association with 
10,000 simulations and top 10 SNPs for each gene. We use 
list of pairs (gene, p value) in a randomization process for 
each module of a GCN. Given the set of n genes in the GCN, 
G, and for a module m, with size k, the genes in that mod-
ule, G(m), we calculated a observed z-score for that module 
given by
where x = 1∕k∑k
i=1
(− log 10(pval(gi))), with gi being the ith 
gene in G(m), X̄ corresponds to x when applied to all genes 
in the network, 휎(X) is the standard deviation of the same 
values. To obtain an empirical p value of the significance of 
the observed z, we generate 10,000 random gene modules, 
sampling from G, with size k to generate a null distribution 
of z-scores as in the expression above. Final p values are 
corrected a la Bonferroni for multiple testing. The data flow 
in Supplementary Fig. 6b shows a visual description of the 
pipeline.
Stratified LD score regression analysis
We applied stratified LD score regression [16] to test 
whether immune-cell-derived genome-wide annotations 
(eQTLs) were enriched for GWAS heritability of PD [32]. 
Stratified LD score regression uses GWAS summary statis-
tics to estimate genetic heritability attributed to a particu-
lar set of SNPs (i.e., SNPs that are located within genomic 
regions with the annotation). The method provides a meas-
ure of whether this partitioned heritability is significantly 
enriched in the SNPs harnessing the annotation. We added 
the annotations individually to the baseline model that has 
been specified in Finucane et al. [16], and used the Hap-
Map Project Phase 3 SNPs for the regression and the 1000 
Genomes Project Phase 3 European population SNPs for 
LD information. We only considered SNPs with a minor 
z =
(x − X̄)
𝜎(X)
allele frequency > 5%, and we excluded the MHC region 
from the analysis.
Results
TLR4‑MyD88 expression and significance 
in PD‑relevant brain regions
We first explored the relevance of TLR4/TLR2-MyD88 sig-
nalling in human brain using publicly available cell-specific 
transcriptomic data [56]. RNA sequencing of purified cell 
types derived from human cortex demonstrated that while 
TLR2 is expressed almost exclusively in microglia, TLR4 
and MyD88 are expressed by human astrocytes and micro-
glia. Furthermore, comparison with murine cortex showed 
that TLR4 expression in human glia is higher than in mouse 
(Supplementary Fig. 1) [55] and that while TLR4 is predom-
inantly expressed by mouse microglia, in humans mature 
astrocytes also express high levels of this gene [55].
Given that cell type-specific RNA sequencing data in 
humans was derived from only one brain region (temporal 
cortex), we used publicly available data derived from post-
mortem control human brain to further explore TLR4, TLR2 
and MyD88 expression across the human brain, including 
within the substantia nigra and putamen. TLR4 and MyD88 
expression was detectable across the human brain using data 
provided by the UK Brain Expression Consortium (UKBEC, 
[41] and Genotype-Tissue Expression Consortium (GTEx; 
[30]) (Fig. 1), which use independent sample sets and differ-
ent platforms for measuring gene expression. The substantia 
nigra and putamen were amongst the brain regions express-
ing the highest levels of these genes according to both 
resources, though UKBEC data did not include information 
on the spinal cord. However, we noted some discrepancy 
in the pattern of MyD88 expression in particular between 
the UKBEC and GTEx resources, with GTEx reporting 
MyD88 expression as highest in the cerebellum, whereas 
UKBEC reported highest expression in substantia nigra. 
This discrepancy may be due to differences in the platforms 
used to measure expression or in the brain donation and 
collection procedures used by the brain banks from which 
samples were derived [30]. In contrast, TLR2 expression 
was at the detection limits of microarrays [41] and had very 
low expression when measured using RNA sequencing [30].
Given the high expression of TLR4 and MyD88 in the 
substantia nigra, we investigated possible functional rela-
tionships between these genes and genes causally implicated 
in PD through genome-wide association studies (GWAS). 
Since the vast majority of risk loci for PD are non-coding 
with the potential to be associated to multiple genes, we 
used the versatile gene-based association study method 
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(VEGAS) [29] to assign risk SNPs to genes, basing the 
analysis on GWAS data from the International Parkinson’s 
Disease Genomics Consortium [32]. This approach incorpo-
rates information from all SNPs within a gene and accounts 
for linkage disequilibrium between SNPs using simulations 
from the multivariate normal distribution to produce gene-
based (as opposed to SNP-based) association p values. Next, 
we applied gene co-expression analysis to transcriptomic 
data from control human brain, originating from UKBEC 
(see Supplementary Fig. 2 for a visual description of the 
pipeline) with the aim of grouping genes into biologically 
meaningful modules in an unsupervised manner. In this 
way, we hoped to identify novel gene relationships, includ-
ing possible relationships between TLR4-MyD88 signalling 
and genes associated with complex PD. Finally, we tested 
all gene co-expression modules for evidence of enrichment 
of genes associated with PD (as determined using VEGAS) 
and results showed a significant enrichment within MyD88-
containing modules in the putamen and medulla (putamen, 
enrichment p value = 2.20 ×  10−3; medulla, enrichment p 
value = 2.92 ×  10−2; Supplementary Table 1).
Fig. 1  Expression patterns of TLR4 and MyD88 genes in pathologi-
cally confirmed normal human brains. a TLR4 expression in control 
human brain as reported by UKBEC. b TLR4 expression in control 
human brain as reported by the GTEx consortium. c MyD88 expres-
sion in control human brain as reported by UKBEC. d MyD88 
expression in control human brain as reported by the GTEx consor-
tium. CRBL cerebellum, FCTX frontal cortex, HIPP hippocampus, 
MEDU medulla, OCTX occipital cortex, PUTM putamen, SNIG sub-
stantia nigra, TCTX temporal cortex, THAL thalamus, WHMT white 
matter
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Interestingly, these modules were not only significantly 
enriched for PD-associated genes, but for microglial markers 
(putamen module p value = 3.84 ×  10−9; medulla module 
p value 3.05 ×  10−7) with some evidence for the more spe-
cific involvement of activated (Type 2) microglia in puta-
men (putamen module p value 1.01 ×  10−4). To robustly 
asses the genetic evidence for the specific involvement of 
type 2 microglia in PD, we used stratified LD score regres-
sion to determine if functional marks for activated innate 
immune cells were enriched for genetic heritability. Given 
the absence of state-specific data for human microglia, we 
used expression-quantitative trait loci (eQTLs) generated 
from monocytes at rest and following activation to address 
this question [14, 39]. This approach demonstrated signifi-
cant heritability enrichment for PD in eQTLs identified in 
lipopolysaccharide (Bonferroni-corrected p value = 1.05 × 
 10−2), but not interferon-γ-activated monocytes (Bonferroni-
corrected p value = 0.20) or untreated monocytes (using 
data from Raj et al. Bonferroni-corrected p value = 0.39; 
using data from Fairfax et al. p value = 0.21). Given that 
monocyte activation by lipopolysaccharide occurs through 
TLR4-MyD88 signalling these findings suggested that 
TLR4-mediated activation of microglia/astrocytes generated 
a cell state of key importance in the development of PD. 
This finding is consistent with previous reports highlighting 
the involvement of the immune system in sporadic PD [5, 
17, 38, 51].
Characterization of the oligomeric α‑syn used in cell 
experiments
To determine the mechanism by which physiological con-
centrations of α-syn oligomers activate microglial and astro-
cytes, we performed experiments on cells in culture so that 
experiments could be performed under controlled condi-
tions, using well-characterized solutions of small soluble 
oligomers. We generated synthetic aggregates of unlabeled 
α-syn by taking aliquots of α-syn solution directly from an 
aggregation reaction at the end of the lag phase. Using sin-
gle-aggregate imaging with Thioflavin T (ThT), we counted 
the number of aggregates present to ensure that each reaction 
was reproducible [20].
Our previous work using single-molecule Förster Reso-
nance Energy Transfer (sm-FRET) aggregating the same 
concentration of dye-labeled α-syn monomer showed that 
approximately 1% of the total solution would be oligomeric 
[7, 23]. We have confirmed these sm-FRET results using 
both SEC [6] and TEM [20]. The small-soluble high-FRET 
oligomers that are formed under these conditions, by a slow 
conversion process from low-FRET oligomers, were found 
to be the most toxic species producing increased ROS when 
added to a neuron and astrocyte co-culture [7, 23]. Once 
formed, the oligomers are stable for several hours enabling 
us to dilute the stock aggregation mixture to produce solu-
tions of known initial oligomer and monomer concentration. 
However, since aggregation was performed in a slightly dif-
ferent buffer to be compatible with cell culture, we repeated 
the oligomer characterization.
Experiments using sm-FRET [7, 23] showed that the % 
of oligomers in our preparation was 1.5 ± 0.5% (n = 3, SD) 
at 26.5 h of incubation and 1.7 ± 0.4% (n = 3, SD) after 
50 h (26.5 h of incubation with shaking followed by 24.5 h 
of static incubation) see Supplementary Fig. 3. The derived 
FRET efficiency histograms were centered at E = 0.65 
(Eq. 3), corresponding to high-FRET oligomer type, also in 
good agreement with previous measurements [7, 21, 23] and 
confirmed that they were smaller than 20 mers.
It is also possible that additional oligomers are formed 
during the incubation with cells for 24 h before buffer is 
exchanged. To test this, we performed experiments with 
unlabeled protein. Both monomer only and preformed oli-
gomers were added to cells (Supplementary Fig. 4). α-syn 
monomer was only incubated with BV2 microglia cells at 
concentrations ranging between 10 pM–4000 nM and left 
for 24–120 h. The supernatant of the cells was then removed 
and analyzed by either ThT fluorescence or ELISA. Under 
conditions where α-syn monomers were incubated with the 
microglia cells at a concentration less than 1 nM, no signifi-
cant (p = 0.8) increase in fluorescence was observed using 
bulk ThT assays and no increase in cytokine production was 
recorded with ELISA’s. 200 nM monomer left for 24 to 48 h 
also showed very minimal aggregation but oligomer for-
mation was detectable for longer times, since an increase 
in TNF-α production and ThT signal was observed and 
aggregates could be detected by direct imaging. Similarly, 
1000 nM monomer left for 24 h showed minimal aggre-
gation but significant TNF-α production beyond this time 
compared to the media control (p = 0.006). We also added 
preformed oligomers, with monomer, to cells. Direct imag-
ing of the number of aggregates in the solution before and 
after incubation with cells for 24 h, using ThT imaging, con-
firmed that there was only a detectable increase in oligomer 
number at 1000 nM monomer (approximately double) and 
no detectable increase at lower monomer concentrations. 
Overall, these experiments show that for incubations below 
1000 nM monomer and 15 nM oligomers, there is no sig-
nificant increase in oligomer concentration over the 24-h 
incubation.
To determine how long we could perform experiments, 
cell survivability experiments were performed. Cells were 
grown to a density of 0.4 ×  106 cells/ml and α-syn oligom-
ers in new cell media introduced. Supernatants were taken 
each day and fresh buffer added, after wells were washed 
in LPS-free PBS. Four concentrations of oligomeric α-syn 
were used to test the effect oligomer concentration had on 
survival. An approximate 90% survival (compared against 
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hour 0) in cell population was observed up to the 96 h mark 
with 1000 nM oligomer or lower, see Supplementary Fig. 5.
Oligomeric α‑syn‑induced cytokine production 
is predominantly generated by TLR4‑dependent 
MyD88 signalling
Initial experiments established that soluble oligomers, but 
not monomers or fibrils, induced an inflammatory response 
from the same initial preparation of α-syn monomer (Fig. 2). 
This confirmed that there was minimal or no LPS contami-
nation in the α-syn preparation. Immortalised murine micro-
glia cells (BV2) were incubated with monomeric, oligomeric 
or fibril forms of α-syn at varying monomer concentrations 
and left at 37 °C for 24 h. Levels of TNF-α, IL-1β and 
NO were then measured in the cell supernatant by ELISA 
(Fig. 2). As expected, the incubation of these cells with the 
TLR4 agonist LPS (at ng/ml concentrations) induces robust 
activation of this receptor.
The α-syn oligomers (70 µM total monomer contain-
ing approximately 100 nM oligomers) produced 750 pg/
ml of TNF-α in comparison to the same concentration of 
the monomer or fibril solutions (40 and 25 pg/ml, respec-
tively). At this oligomer concentration, considerable cell 
death occurred by 24 h (33% cell death compared to day 
0, see Supplementary Fig. 5a). Increasing concentrations 
of fibril or monomer samples (Fig. 2c) failed to show a sig-
nificant increase in TNF-α production confirming that only 
oligomers cause an inflammatory response, as previously 
reported [6, 8].
To determine which receptors were involved in the 
immune response, previously characterized immortalized 
murine bone marrow-derived macrophage cells were used 
derived from mice lacking either TLR4, TLR2 or MyD88 
[22, 24, 46]. These cells were incubated with different con-
centrations of α-syn oligomers or monomers for 24 h. The 
cytokine levels present in the cell supernatant were then 
analyzed by ELISA (Fig. 3). As expected in wild-type cells, 
Fig. 2  Aggregation of  αS  and the pro-inflammatory response of 
microglial cells to different  αS  aggregates.  a  ThT single-molecule 
fluorescence imaging of α-syn aggregates after 24  h of aggrega-
tion of 10  µM monomer. Significant increase of aggregates (p < 
0.01) is observed. Scale bar represents 5 µm. b Bulk   ThT assay of 
α-syn  (10 µM)  aggregation when left at 37 °C in a shaking incubator 
(200 rpm) over a period of 96 h (n = 8 sem). c The pro-inflammatory 
response, as measured by TNF-α production, of BV2 microglia after 
a 24-h incubation with αS-only monomers, oligomers, and fibril sam-
ples (0.05–200 μM total monomer) compared to LPS (0.05–200 ng/
ml) stimulation (n = 5, sem). Monomer or fibrils produce signifi-
cantly less TNF-α compared to oligomers over all concentrations 
(monomers p = 0.0029, fibrils p = 0.0018, one way ANOVA with 
post hoc Tukey)
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Fig. 3  Pro-inflammatory response of TLR4, MyD88 or TLR2 knock-
out macrophages to αS oligomers. Cells were stimulated with αS oli-
gomers (1–4000 nM (total monomer concentration)) or αS fibrils for 
24 h. The levels of the pro-inflammatory mediators TNF-α, IL-1β and 
NO were measured. a TNF-α production is significantly reduced with 
increasing oligomer concentration in the knockout cells compared to 
wild-type (TLR4−/− p = 0.0015, MyD88−/− p = 0.006,  TLR2−/− p = 
0.02) (n = 5, sem). b  IL-1β production is significantly reduced with 
increasing oligomer concentration in the knockout cells compared to 
wild-type  (TLR4−/−  p = 0.0015, MyD88−/− p = 0.006,  TLR2−/− p = 
0.008) (n = 4, sem). c NO production is significantly reduced   with 
increasing oligomer concentrations in the knockout cells compared 
to wild-type (TLR4−/− p = 0.0014,  MyD88−/− p = 0.002,  TLR2−/− p 
= 0.03 (n = 3, sem). All statistical comparisons among groups were 
performed using one-way ANOVA, followed by the Tukey’s post hoc 
test
Fig. 4  Response of BV2 microglial cells and astrocytes to α-syn 
oligomers and the blocking of TNF-α production by TLR4 antago-
nists. a Time course of TNF-α production by BV2 cells in response 
to sustained exposure to αS-oligomers (10  pM–1  nM (n = 3, sem). 
Buffer was exchanged every 24  h. b The response of astrocytes to 
αS-monomers, αS-oligomers and αS-Fibrils (0.05–200 μM (total 
monomer concentrations)) compared to LPS (0.05–200  ng/ml) 
stimulation stimulation for 24 h (n = 4, sem). A statistically signifi-
cant increase was observed in response to oligomer vs monomers (p 
= 0.0041) and in oligomer vs fibrils (p = 0.0078). c Time course of 
TNF-α production by astrocytes in response to sustained exposure to 
αS-oligomers (10 pM–1 nM). Buffer was exchanged every 24 h (n = 
4, sem). After 72 h a significant increase in response was observed in 
response to αS-oligomers compared to unstimulated cells (p = 0.009 
at 72 h, p = 0.0036 at 120 h). d The response of astrocytes after a 
24 h incubation with αS-oligomers only, αS-oligomers and the TLR4 
antagonist RSLA and TAK242, LPS with RSLA and RSLA only (n = 
3, sem). Both RSLA (p = 0.0165) and TAK-242 (p = 0.0204) show 
a statistically significant decrease when added with αS-oligomers, 
compared to αS-oligomers alone. All statistical comparisons among 
groups were performed using one-way ANOVA with post hoc Tukey 
test
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cytokine production was seen only with oligomers and not 
monomers.
In  TLR4−/− cells, the inflammatory response to oli-
gomers (TNF-α, Il-1β and NO) was significantly reduced 
compared to wild-type cells, ~ 10 to ~ 100 fold decrease. 
Likewise, in  MyD88−/− cells and to a much lesser degree in 
 TLR2−/− cells there was statistically significant decreased 
TNF-α, IL-1β and NO production compared to wild-type 
cells. Overall, these experiments show that TLR4 signalling 
through MyD88 is the dominant pathway by which α-syn 
oligomers are recognised by macrophages. TLR2 plays a 
more minor role in α-syn-induced inflammation. Since only 
α-syn oligomers cause signalling, the α-syn oligomer con-
centration used here is quoted for the rest of the paper.
Low concentrations of α‑syn oligomers sensitizes 
inflammatory responses through TLR4
Oligomer concentrations in the CSF of patients suffering 
from PD are of the order of 1–10 pM. We, therefore, incu-
bated BV2 microglial cells with lower concentrations of 
α-syn oligomers (1 nM–10 pM), together with α-syn mono-
mer (100–1 nM), for a sustained period of time (up to 5 days; 
Fig. 4a) and measured supernatant cytokine production at 
24, 48, 72 and 120 h. Lower oligomer concentrations no 
longer killed the BV2 cells. Significant (p = 0.009) induc-
tion of pro-inflammatory cytokines in response to α-syn oli-
gomers, compared to unstimulated cells, was observed. Rat 
astrocytes produce a response to α-syn oligomers but not 
monomer or fibrils (Fig. 4b) and this response was detect-
able at low pM oligomer concentrations after 72 h of incu-
bation (Fig. 4c, p = 0.009, compared against unstimulated 
cells). There was no significant cytokine production in TLR4 
knockout macrophage cells (Supplementary Fig. 6) indicat-
ing that TLR4 is required for signalling. By 120 h α-syn 
oligomer stimulated cells started to die so longer incubations 
times were not feasible (Supplementary Fig. 5a). This α-syn 
sensitization response was effectively inhibited by the TLR4 
antagonists RSLA or TAK-242 (Fig. 4d).
Assuming increased mRNA expression of TLR4 in 
human glia is indicative of higher protein expression then 
this would be expected to result in increased levels of TNF-α 
on exposure to oligomer concentrations. Experiments on cul-
tured human astrocytes explicitly tested this prediction and 
confirmed that sensitization also occurred at low-oligomer 
concentrations (Supplementary Fig. 7) and was significantly 
reduced by TLR4 antagonists (Supplementary Fig. 8).
α‑syn oligomer‑induced inflammatory sensitization 
is reversible
To determine whether microglia could recover if α-syn oli-
gomers were removed from the cells we measured TNF-α 
production over time, after exposure of BV2 microglia to 
α-syn oligomers for 72 h followed by oligomer removal 
(Fig. 5). The production of TNF-α decreases slowly with 
time, but is not completely restored to basal levels after 2 
days. To determine whether TLR4 inhibitors could also 
reverse α-syn oligomer-induced sensitization, BV2 cells 
were incubated with α-syn oligomers for 24–72 h. Cells 
were washed and the media replaced with RSLA and fresh 
α-syn oligomers and a marked reduction in TNF-α produc-
tion was seen in the following 48–72 h (Fig. 5b–d). Cell 
viability showed no significant change (Supplementary 
Fig. 5b). These data suggest the α-syn sensitization is revers-
ible if α-syn oligomers are removed from the cells or if the 
cells are incubated with a TLR4 antagonist even if α-syn 
oligomers are still present in the media.
TLR4 antagonists protect neurons 
from oligomer‑induced toxicity
α-syn oligomers can cause excessive ROS generation, and 
cell death in neurons. To determine the role of TLR4 sig-
nalling in ROS and cell death we used TLR4 antagonists. 
We also used an extracellular chaperone, clusterin, to bind 
the oligomers and block all oligomer-induced processes. 
Clusterin preferentially binds amyloid beta oligomers over 
monomers [33, 34] and been shown to have an effect on 
α-syn [43].
To test the effect of clusterin, RSLA and TAK242 on 
the production of ROS, we used dihydroethidium (DHE) 
dye which allowed us to measure the rate of oxidation 
of the dye by cellular superoxide production. Rat co-cul-
tures of neurons and astrocytes were treated with either 
1 μM TAK242 or 0.1 μg/ml RA-LPS for 30 min prior to 
application of oligomers to the culture. Clusterin was pre-
incubated with α-syn oligomers before application to the 
cells. The production of ROS (mainly superoxide) after 
application of the α-syn oligomers was compared to the 
basal level (Fig. 6a). The results showed that α-syn oli-
gomers produced significantly increased levels of ROS, 
approximately 4-fold as shown previously, and this over-
production was prevented in cells pre-treated with TLR4 
inhibitors, RSLA and TAK242. ROS production was also 
reduced by pre-incubation with clusterin. Application 
of oligomers for 24 h induced cell death, as previously 
shown. Oligomer induced cell death in the rat co-culture 
was reduced to basal levels by both clusterin and the TLR4 
antagonist RSLA (Fig. 6aiii). Interestingly, clusterin was 
less effective when used in experiments on BV2 cells and 
significantly higher clusterin concentrations were needed 
for a reduction in TNF-α to be observed (Supplementary 
Fig. 9). Clusterin needs to bind to the oligomers to prevent 
TLR4 signalling but only a few TLR4 receptors need to 
signal for cytokine production. Therefore, both the number 
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of TLR4 receptors and the number of oligomers that are 
not bound or partially bound by clusterin will determine 
the extent of TLR4 signalling and resulting cell death. 
This result suggest that targeting TLR4 directly may be a 
more effective strategy than binding the oligomers, espe-
cially if TLR4 expression is high as is presumably the case 
with BV2 cells.
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Next, we tested whether TLR4 inhibitors reduced 
the α-syn oligomer-induced cell toxicity in rodent neu-
rons, astrocytes and co-cultures of neurons and astrocytes 
(Fig. 6ci–iii, ei–iii). Cell preparations were characterized 
for neuronal and astrocyte enrichment using the markers 
β-III Tubulin and GFAP (Fig. 6bi). Neuron-enriched cul-
tures contained 90% ± 1.3% β-III Tubulin-positive cells and 
astrocyte enriched cultures contained 97% ± 0.1% GFAP-
positive cells. Neuron-astrocyte co-cultures contained 
43 ± 1.1% neurons and 50 ± 1.2% astrocytes (Fig. 6bii). 
Cells were incubated with α-syn oligomers with or without 
RSLA or TAK242 overnight, and cell death was assessed 
by automated counting of the number of dead cells (labelled 
with sytox green) and number of total cells (Hoechst) (Sup-
plementary Fig. 10a). We also measured the amount of 
TNF-α production (Supplementary Fig. 11a). Neuronal cell 
death was significantly increased by α-syn oligomers (p = 
7.673E-5) in the enriched neuronal cell culture, and this 
was not affected by TLR4 blockade (Fig. 6ci). Oligomers 
also induced very low level, but highly significant, toxic-
ity to astrocytes (p = 6.968E − 8), and this was prevented 
by TLR4 antagonists (RSLA; p = 7.746E-8, TAK242; p 
= 8.103E − 8, Fig. 6cii). Notably, the oligomers induced 
significant cell death in the neuron-astrocyte co-culture (p = 
4.493E-4), and this was reduced to basal levels by the pres-
ence of the TLR4 inhibitors (RSLA; p = 1.127E-4, TAK242; 
p = 0.001, Fig. 6ciii) and TNF-α levels reduced to basal 
levels (Supplementary Fig. 11a). This data suggested that 
astrocytes are able to drive cell death in rodent co-cultures 
through oligomer-induced TLR4 signaling.
As we have reported that α-syn oligomers drive human 
astrocytic production of TNF-α (Supplementary Figs. 7, 
8) via TLR4-dependent pathways, we tested the effect of 
TLR4 inhibition on oligomer induced cell toxicity in a 
primary human model (Fig. 6d, e). We generated enriched 
human neuronal cultures (92 ± 2.1% β-III Tubulin-posi-
tive cells), enriched human astrocyte cultures (99 ± 1.2% 
GFAP) and a neuron-astrocyte co-culture (β-III Tubulin: 
52 ± 2.8%, GFAP: 43 ± 3.2%, Fig. 6dii). Application of 
α-syn oligomers induced significant levels of cell death 
in both the enriched neuron (p = 0.046, Fig. 6ei) and the 
enriched astrocyte (p = 0.0288, Fig. 6eii) cultures. As 
noted with the rodent cells, the oligomer-induced neuronal 
death was not abolished by TLR4 blockade in the absence 
of astrocytes (Fig. 6ei). TLR4 antagonism did show a ten-
dency to prevent oligomer-induced astrocytic cell death 
(Fig. 6eii). Importantly, in the human neuron-astrocyte 
co-culture experiment, oligomer-induced cell death was 
prevented by the application of TLR4 antagonists RSLA 
and TAK242 (p = 0.048 and p = 0.0333, respectively, 
Fig. 6iii, Supplementary Fig. 10b) and the TNF-α levels 
reduced to basal levels (Supplementary Fig. 11b).
We estimated the proportion of astrocytic and neuronal 
cell death in the co-culture experiment, by sampling the 
nuclear size of neurons versus astrocytes from the enriched 
cultures, and segmenting the sytox green-positive nuclei 
on the basis of size in the co-cultures (Supplementary 
Fig. 12). For both the rodent and human co-culture, the 
majority of the oligomer-induced cell death was neuronal 
rather than astrocytic (91 ± 2.6% in rodent and 68 ± 2.9% 
in human co-culture preparation).
Taken together, this data shows that oligomers are able 
to induce neuronal toxicity through two mechanisms: neu-
rons alone are directly susceptible to oligomer-induced 
TLR4-independent toxicity. However, in the presence of 
astrocytes, the dominant mechanism of oligomer-induced 
neuronal cell death is TLR4-dependent oligomer-induced 
activation of astrocytes leading to the production of TNF-α 
and other cytokines by astrocytes.
Discussion
Sporadic PD is not caused by a single-gene mutation but 
rather a large number of different genes and environmental 
factors contribute. For this reason, we used transcriptomic 
data from humans as a starting point to determine the rel-
evance of TLR2 and TLR4 signalling in the initiation 
of PD. Our analysis of human brain transcriptomic data 
shows that of all brain regions analyzed, the substantia 
nigra has the highest levels of TLR4 expression. Further-
more, integrative analyses, which make use of PD GWAS 
data with gene co-expression networks in human brain, 
suggest a causal role for microglial MyD88-dependent 
signalling in PD. Taken together, this supports the con-
cept that TLR4-MyD88 signalling via both astrocytes 
and microglial plays a key role in the onset of PD and 
explains the selective vulnerability of the substantia nigra. 
Fig. 5  Reversal of α-syn oligomer-induction of cell priming. The pro-
inflammatory response (induction of TNF-α) by BV2 microglia after 
priming with oligomeric α-syn was determined by ELISA. a BV2 
microglia were primed with 2 nM, 1 nM or 200 pM concentrations 
of α-syn oligomers for 72 h before α-syn was removed and replaced 
with fresh buffer. TNF-α levels were measured every 12 h by replac-
ing the solution above the cells with fresh buffer. The production of 
TNF-α decreases slowly with time, but is not completely restored to 
the unprimed state (n = 3, sem). 2 nM, 1 nM and 200 pM oligomer 
is significantly higher than untreated cells at all times (p = 0029, p = 
0.0056 and p = 0.087 respectively). b–d BV2 microglia were incu-
bated with oligomeric α-syn, 2–2000 nM. Cells were primed for dif-
ferent lengths of time (b 24-h, c 48-h, d 72-h) before α-syn oligom-
ers were removed, cells were washed with media and replaced with 
media containing α-syn oligomers and the TLR4 antagonist RSLA. 
RSLA reduced TNF-α production and enhanced cell survival return-
ing viability to 90% (± 3%) over the duration of the experiment (Sup-
plementary Fig. 5b) (n = 4, sem). All statistical comparisons among 
groups were performed using one-way ANOVA with post hoc Tukey 
test
◂
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To elucidate the mechanism by which this occurred, we 
then performed experiments at physiological concentra-
tions of oligomers. Under these conditions, α-syn oligom-
ers are capable of provoking an immunological response 
from microglia and astrocytes and TLR4 receptors pro-
duce the majority of the activation of cytokine production. 
Immortalised mouse microglial cells as well as TLR4 and 
MyD88 knockout macrophage cells have all been used 
to test the cytokine response to α-syn oligomers. When 
MyD88 is absent, the cells were still able to produce a 
low level of inflammatory cytokines suggesting α-syn 
oligomer-induced TLR4-dependent cytokine production 
is also being induced by TRIF-dependent signalling [52]. 
Our work suggests that TLR2 plays a minor role in both 
the α-syn-induced TNF-α production and the initiation of 
PD. This is in agreement with other published work [15, 
42] although some studies propose a more dominant role 
for this receptor [8, 25]. TLR2 expression is upregulated 
upon activation of TLR4 [48] so it is possible that α-syn 
activation of TLR4 not only leads to direct generation of 
inflammatory signalling, but also enhances inflammatory 
signalling through other TLRs. The increase in expres-
sion of TLR2, for example, may either result in enhanced 
sensitivity of this receptor to TLR2 ligands and/or to a net 
increase in TLR2 signalling to these ligands and occur 
later in the progression of the disease. Importantly, our 
data shows a significantly higher sensitivity of TLR4 to 
oligomers than TLR2 at low oligomer concentrations sug-
gesting that TLR4 will be the major receptor at physiologi-
cal conditions and that TLR4 signalling involves MyD88.
Our data show that there is a sensitization or training 
[35] of the immune response in macrophage and micro-
glial responsiveness over time to a constant low-level dose 
of α-syn oligomers. Sensitization or priming has been 
reported for experiments using LPS, which acts via TLR4, 
as a systemic challenge [31] but not by protein aggregates, 
to our knowledge and not by continual dosing. Low levels 
of LPS lead to an increased reaction to a secondary chal-
lenge [9], although the mechanism by which this occurs 
remains to be established. In contrast, high doses of LPS 
lead to tolerance [53]. Furthermore, it is known that cells 
become sensitized with age [1] and also, once primed, give 
a larger response to a secondary challenge such as addi-
tion of LPS or infection [36]. Importantly, and in contrast 
to the LPS effects, we observed sensitization to continual 
low-dose exposure. Therefore, no increase in oligomer 
concentration, and no rechallenge experiment is required 
to demonstrate the effect, allowing us to utilize a physi-
ologically relevant experimental paradigm.
While it is well known that protein aggregation, neu-
roinflammation and oxidative stress all contribute to the 
onset of PD, it is not known what the initial cause is. Our 
experiments show that an inflammatory response can occur 
without any increase in oligomer concentration from the 
physiological levels. The production of cytokines such as 
TNF-α leads to oxidative stress which is known to lead to 
altered mitochondrial function [10]. These conditions can 
then result in increased protein aggregation, further increas-
ing TLR4 signalling, and leading ultimately to the formation 
of Lewy Bodies and cell death. While there are potential 
issues extrapolating from these cell experiments to animals, 
this finding is also supported by the MPTP inflammatory 
model of PD, where TLR4 knockout mice were protected 
[37]. Prolonged exposure to low levels of TLR4 agonists 
leads to switching to a pro-inflammatory response, which 
increases with time and so cannot be reversed without inter-
vention. Furthermore, it is recognized that patients with PD 
suffering from intercurrent infective/inflammatory illnesses 
undergo deterioration in their PD, and a variety of reasons 
have been suggested to underlie this [3]. Our data would 
support the hypothesis that systemic inflammatory cytokines 
may accelerate the cytokine-induced neuronal damage that 
drives PD pathogenesis.
It has been extensively reported that oligomers interact 
directly with neurons to induce synaptic dysfunction, cal-
cium dysregulation, mitochondrial dysfunction and oxidative 
stress. Here, we show that significant neuronal damage is 
mediated by the interaction between α-syn oligomers and 
astrocytes/microglia resulting in the release of cytokines that 
cause damaging effects on neurons. Our transcriptomic and 
Fig. 6  Live cell imaging of α-syn oligomer induced cell toxicity, 
and dependence on TLR4. An oligomeric solution containing 1 μM 
monomer and approximately 10  nM oligomers were used with or 
without a range of inhibitors (RSLA, Clusterin, TAK242). ai α-syn 
oligomer induced ROS was measured in rat cortical neuron and astro-
cyte co-culture using a ratio of dihydroethydium (Het) fluorescence 
between its oxidized and non-oxidized forms. 0.1  μg/ml RLSA or 
1uM TAK242 reduced overproduction of ROS induced by α -syn oli-
gomer (n = 3, sem). Clusterin, RSLA or TAK242 alone did not pro-
duce an increase in ROS (data not shown). aii Representative traces 
from the ROS measurement show that treatment with TLR4 inhibi-
tors reduced the ratio of Het fluorescence in comparison to α-syn oli-
gomer alone. aiii Cell death assay was performed using Propidium 
Iodide (PI) under the same conditions but cells were incubated over-
night with each inhibitor, Clusterin, RSLA or TAK242 (n = 2, sem). 
Oligomers induced an increase in cell death whilst all three inhibi-
tors prevented cell death. aiv Representative images from cell death 
assay. bi Representative images showing rodent neurons and astro-
cytes bii Quantification of cell type in cultures. ci–iii Cell death was 
measured in enriched rodent neurons and astrocytes and co-cultures: 
(i) neurons, (ii) astrocyte, (iii) co-culture preparation. (n = 3, sem). 
di Representative images showing human neurons and astrocytes. dii 
Quantification of cell type in cultures. ei–iii Cell death was measured 
in enriched human neurons and astrocytes and co-culture: (i) neurons, 
(ii) astrocyte, (iii) co-culture preparation. (n = 2, sem). No-treat: no 
treatment, Monomer: 1 μM a-syn monomer, Oligomer; 10 nM α-syn 
oligomer, O + RSLA: 10 nM α-syn oligomer + 0.1ug/ml RSLA, O 
+ TAK: 10 nM α-syn oligomer + 1 μM TAK242. All statistical com-
parisons among groups were performed using one-way ANOVA, fol-
lowed by the Tukey’s post hoc test
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genomic analysis shows that this interaction appears crucial 
in the early stages of PD pathogenesis, so that therapies that 
target low-grade inflammation may be useful in treatment 
of PD.
In summary, we have found that extended doses of physi-
ological concentrations of α-syn oligomers sensitizes the 
production of proinflammatory cytokines by the TLR4 
receptor in both microglial cell lines and astrocytes and 
that the response increases with time. This observation pro-
vides an explanation for the switch to a proinflammatory 
response observed in PD and suggests, in combination with 
transcriptomic analysis, that sensitization of glial cells is a 
very early event in PD, driving the disease and increasing 
ROS production and cell death in neurons. Sensitization of 
the innate immune system by low concentrations of protein 
aggregates may also play an important early role in other 
neurodegenerative diseases. Rather than viewing PD as a 
protein aggregation disease, where increased protein aggre-
gation initiates disease, our work suggests that PD can also 
be considered to be a neuroinflammatory disease, initiated 
by sensitized astrocytes and microglia.
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